Synthetic vs. Real-World Clinical Data: What Actually Trains Better Medical AI

If you build models on health data, you eventually face one fork in the road: generate patients, or source them. Synthetic clinical data is fast, private, and infinitely scalable. Real-world clinical data is messy, governed, and irreplaceable. The honest answer to "which trains better medical AI" is "it depends on what you are teaching the model" — and the boundary between the two is sharper and more predictable than the marketing on either side suggests.

This is a fair-minded map of that boundary: what synthetic data is genuinely good for, the specific places it breaks, and when real-world data is the only thing that works.

What "synthetic" and "real-world" actually mean

Real-world clinical data is generated by the act of caring for patients: encounters, diagnoses, labs, medications, procedures, and the timestamps that connect them. It is observational. Nobody designed it to be tidy, which is precisely why it carries the signal of how medicine actually unfolds.

Synthetic clinical data is manufactured to resemble real data without describing any real person. There are two broad families. Rules-and-simulation generators — the best-known being Synthea, an open-source engine from MITRE — simulate a patient's life from birth using disease-progression modules built on published incidence, prevalence, and care-guideline statistics. Model-based generators instead learn a statistical distribution from a real dataset and sample new "patients" from it (GANs, diffusion models, and increasingly LLM-driven approaches).

Both produce records that look clinically plausible. Plausible is not the same as faithful, and the gap is where model performance lives.

Where synthetic data genuinely helps

Synthetic data earns its place. It is not a consolation prize.

• Plumbing and prototyping. Pipelines, schema mapping, ETL into OMOP or FHIR, dashboards, and integration tests all need realistic-shaped data long before you should expose a model to protected health information. Synthetic records are free of privacy, cost, and access friction, so engineering can move while governance catches up.
• Rare-event augmentation. When a condition or adverse event is too sparse to learn from, synthetic samples can rebalance a training set so the minority class is actually learnable. Used as augmentation — not as the whole diet — this is a well-supported technique.
• Scenario coverage and stress tests. You can manufacture edge cases on demand: an implausible lab combination, a specific drug-allergy collision, a demographic the real cohort under-represents. That is hard to do with observational data you do not control.
• Sharing and teaching. Synthetic cohorts can be published openly for benchmarking, coursework, and reproducibility without consent or re-identification risk.

For these jobs, synthetic data is often the better choice, not merely an acceptable one. The trouble starts when teams ask it to stand in for reality during the part of training that determines clinical behavior.

Where synthetic data breaks: three failure modes

The breakages are not random. They cluster in three places, and they are the three things medicine is actually made of.

1. Comorbidity interaction. Real patients are bundles of interacting conditions. Diabetes changes how heart failure presents; chronic kidney disease changes which drugs are safe; one diagnosis reshapes the probability and the management of the next. Rules-based generators tend to model each disease module in relative isolation, so the joint distribution — the way conditions co-occur and modify one another — is thinner than reality. A model trained there can learn each disease in a vacuum and then stumble on the multi-morbid patient who is the norm in any real clinic.

2. Long-range temporal coherence. A real medical history is a coherent narrative across years: a diagnosis leads to a medication, which produces a lab trend, which triggers a dose change, which precedes a complication. Synthetic generators are good at local plausibility (any single visit looks fine) but weaker at the long arc — the causal, sequenced dependency between an event now and a consequence three years later. Models that depend on trajectory — progression prediction, time-to-event, treatment-response — are the most exposed to this gap.

3. Real co-occurrence and the "unknown unknowns." Observational data encodes correlations nobody wrote down: documentation habits, referral patterns, the messy ways variables travel together. Model-based generators can only reproduce the structure they were trained to see, and validation work on leading generators has repeatedly found that some real-world statistical relationships are not faithfully preserved. Synthetic data also cannot invent confounders that were never in the source. Train exclusively on it and a model risks learning generator artifacts instead of biology — patterns that look like signal and evaporate on real patients.

The throughline: synthetic data reproduces the structure its makers understood and specified. Real-world data carries the structure nobody knew to specify — and that residual is often exactly what a clinically useful model needs to learn.

When real-world data wins

Reach for real-world clinical data when the model's job is to reason about reality as it actually behaves:

• Outcomes and prognosis, where the dependent variable is a real consequence, not a simulated one.
• Treatment-effect and real-world-evidence work, where the entire point is to observe what happened to comparable patients under real conditions.
• Multi-morbidity and rare real interactions, where the joint distribution — not any single axis — is the signal.
• Final validation, always. Whatever you train on, performance has to be confirmed on held-out real data before anyone trusts it near a clinical decision.

This is also where data quality compounds. Real-world data is only as good as its coding, completeness, and longitudinal continuity. Records that are de-identified, consistently coded, and connected across time — so a patient's history reads as one coherent thread rather than disconnected fragments — are far more valuable for training than a larger pile of shallow, inconsistent snapshots.

This article is educational and not regulatory, clinical, or legal advice; real-world evidence intended to support regulatory decisions carries specific provenance, quality, and documentation requirements you should evaluate with qualified advisors.

A practical playbook: use both, deliberately

The strongest teams do not pick a side. They assign each kind of data to the job it is good at.

1. 01Build on synthetic. Develop pipelines, schemas, and tests against synthetic records so engineering never waits on a data agreement.
2. 02Augment with synthetic, sparingly. Use it to rebalance rare classes and cover edge cases — as a supplement to real records, not a replacement.
3. 03Learn clinical behavior on real-world data. The relationships that determine real performance — comorbidity, trajectory, true co-occurrence — come from observed patients.
4. 04Validate on held-out real data, every time. It is the only honest test of clinical utility and safety.

Treat synthetic data as scaffolding and real-world data as the structural material. Scaffolding lets you build faster and safer; it does not bear the load.

Key takeaways

• Synthetic data excels at plumbing, prototyping, rare-event augmentation, and open sharing — often the better choice for those jobs.
• It predictably weakens on three things: comorbidity interaction, long-range temporal coherence, and real co-occurrence including unknown confounders.
• Real-world clinical data wins for outcomes, real-world evidence, multi-morbidity, and final validation — wherever the model must reason about reality as it behaves.
• The right architecture is "both, deliberately": synthetic for scaffolding and augmentation, real-world for learning clinical behavior and for validation.
• For real-world data, quality beats volume: de-identified, consistently coded, longitudinally connected records carry the signal models actually need.

The bottom line

Synthetic and real-world clinical data are not rivals; they are tools with different load ratings. Synthetic data moves you fast and keeps you private. Real-world, longitudinal, well-coded data is what teaches a model how medicine actually behaves — and what you ultimately validate against. That is the category of asset Prometheus Bio focuses on: de-identified, coded, longitudinal clinical data, refined to be the ground truth your models are measured by.